ID: ALA3817893

Max Phase: Preclinical

Molecular Formula: C15H13F3N2O4S

Molecular Weight: 374.34

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cccc(C2(OCC(F)(F)F)SC=C(C)n3c2noc3=O)c1

Standard InChI:  InChI=1S/C15H13F3N2O4S/c1-9-7-25-15(23-8-14(16,17)18,12-19-24-13(21)20(9)12)10-4-3-5-11(6-10)22-2/h3-7H,8H2,1-2H3

Standard InChI Key:  ZPIYDWZFLJYSJT-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 374.34

Molecular Weight (Monoisotopic): 374.0548

AlogP: 3.19

#Rotatable Bonds: 4

Polar Surface Area: 66.49

Molecular Species: NEUTRAL

HBA: 7

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa:

CX LogP: 3.57

CX LogD: 3.57

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.82

Np Likeness Score: -0.93

References

1. Carosati E, Cosimelli B, Ioan P, Severi E, Katneni K, Chiu FC, Saponara S, Fusi F, Frosini M, Matucci R, Micucci M, Chiarini A, Spinelli D, Budriesi R..  (2016)  Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism.,  59  (7): [PMID:26962886] [10.1021/acs.jmedchem.6b00030]

Source

Source(1):

• Scientific Literature